Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00912847 |
Recruitment Status :
Completed
First Posted : June 3, 2009
Last Update Posted : June 3, 2009
|
Sponsor:
Chinese University of Hong Kong
Information provided by:
Chinese University of Hong Kong
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this study is:
- To establish and compare the diagnostic utilities for hepatocellular carcinoma (HCC) screening tests of (a) HS-AFP, (b) AFP + US,(c) AFP alone and (d) US alone (within HBV carriers between age 40 and 70 years);
- To establish the cost-effectiveness of the screening tests;
- To compare tumor sizes, resection rates, and survival rates up to 18 months between those who were screened by HS-AFP those of a historical control group that was not screened.
Condition or disease |
---|
Hepatitis B Virus |
Study Type : | Observational |
Actual Enrollment : | 1018 participants |
Time Perspective: | Prospective |
Official Title: | Validity and Cost-Effectiveness of a New Screening Test for Hepatocellular Carcinoma |
Study Start Date : | October 1997 |
Actual Primary Completion Date : | April 2004 |
Actual Study Completion Date : | April 2004 |
Resource links provided by the National Library of Medicine

Group/Cohort |
---|
JHC
AFP > 20 ng/ml and USG positive
|
Non JHC
patient without AFP > 20 or USG negative
|
Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Study Population
HBV carriers between age 40 and 70 years
Criteria
Inclusion Criteria:
- Age between 40 and 70 years
- Seropositive for HBsAg
- Child's A or B
- Life expectancy of more than 2 years
Exclusion Criteria:
- Non-HBV related cirrhosis
- History of malignancy
No Contacts or Locations Provided
Responsible Party: | Prof. Tony Mok, Clinical Oncology |
ClinicalTrials.gov Identifier: | NCT00912847 |
Other Study ID Numbers: |
RHCC002 |
First Posted: | June 3, 2009 Key Record Dates |
Last Update Posted: | June 3, 2009 |
Last Verified: | June 2009 |
Keywords provided by Chinese University of Hong Kong:
HBV carriers |
Additional relevant MeSH terms:
Hepatitis B Carcinoma, Hepatocellular Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Hepatitis Liver Diseases Digestive System Diseases |
Adenocarcinoma Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Hepadnaviridae Infections DNA Virus Infections Virus Diseases Hepatitis, Viral, Human |